NCT06162403 Exploring the Benefit of Peripheral Nerve Stimulation in Treating Pain From Chemo-induced Peripheral Neuropathy: A Longitudinal Single Center Feasibility Study
| NCT ID | NCT06162403 |
| Status | Recruiting |
| Phase | — |
| Sponsor | M.D. Anderson Cancer Center |
| Condition | Peripheral Nerve Stimulation |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2024-02-22 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 10 participants in total. It began in 2024-02-22 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To learn if peripheral nerve stimulation (PNS) can help to improve pain in participants with CIPN.
Eligibility Criteria
Inclusion Criteria: * Participants diagnosed with chronic (≥90 days duration) CIPN (due to either vinca alkaloids, taxanes, bortezomib, thalidomide, platinum-based compounds or ionizing irradiation) of the lower extremity, seen at Pain Management Center at MD Anderson Cancer Center * Participants reports baseline pain ≥ 4 (0-10 scale, NRS) * Participants between ages 18-85 years old * Participants who have completed chemotherapy within the previous year at the time of enrollment Exclusion Criteria: * Participants with cognitive dysfunction * Participants with recent history (\<6 months) of drug or alcohol abuse * Participants with open skin lesion or undergoing antibiotic therapy for local for systemic infection * Participants with allergies to local anesthesia, steroids, or adhesives * Participants with conditions that conflict with the SPRINT PNS System Indications for Use, including Contraindications and Warnings.
Contact & Investigator
Saba Javed, MD
PRINCIPAL INVESTIGATOR
M.D. Anderson Cancer Center
Frequently Asked Questions
Who can join the NCT06162403 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Peripheral Nerve Stimulation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06162403 currently recruiting?
Yes, NCT06162403 is actively recruiting participants. Contact the research team at sjaved@mdanderson.org for enrollment information.
Where is the NCT06162403 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT06162403 clinical trial?
NCT06162403 is sponsored by M.D. Anderson Cancer Center. The principal investigator is Saba Javed, MD at M.D. Anderson Cancer Center. The trial plans to enroll 10 participants.